Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Amyris Biotechnologies
So what: There was no news today, but earlier in the week Amyris announced a collaboration and joint development agreement with Switzerland-based Firmenich. Two analysts also initiated coverage on the company earlier in the week, with one "buy" rating and one "neutral" rating.
Now what: Investors seem to be a little late reacting on this one. Amyris looks to be on the right track, but the massive losses it is posting will keep me away from this stock. I would like to see the company at least getting closer to a profit before diving in, despite what analysts say.
Interested in more info on Amyris? Add it to your watchlist here by clicking here.
